ARC, the healthcare innovation arm of Sheba Medical Center, Israel’s largest hospital and a global leader in medical innovation, celebrated last week the official opening of an innovation center at the Cancer Institute (ICO) in Nantes, France. This ceremony marks a key milestone in the strategic collaboration between ARC and ICO, aimed at transforming healthcare innovation in France.
“At Sheba Medical Center, we believe that innovation is built on collaboration. The partnership with ICO embodies our shared vision of pushing the boundaries of what is possible in healthcare. By combining ICO’s world-class expertise in oncology with ARC’s transformative methodologies, we are shaping the future of precision medicine. This initiative is a leading example of how institutions can join forces to drive meaningful change and address today’s most pressing healthcare challenges,” said Professor Yitshak Kreiss, CEO of Sheba Medical Center.
This innovative partnership leverages ARC’s structured methodology to enable ICO, one of France’s leading cancer centers, to strengthen its capabilities in research, patient care, and healthcare innovation. By combining ARC’s expertise in transforming global healthcare systems with ICO’s excellence in oncology, this collaboration sets a new standard for precision medicine innovation.
As part of this initiative, ICO has launched “Impulse by ICO”, a dedicated startup accelerator offering comprehensive support to industry collaborations and early-stage companies. Designed to foster breakthrough technologies that address major challenges in healthcare and oncology, “Impulse by ICO” creates a vibrant innovation ecosystem.
In addition, ICO has developed a state-of-the-art data platform as part of this partnership. This includes a local data warehouse with fully structured datasets and an integrated tumor library to provide enriched data for testing, sequencing and analysis. These resources are designed to advance research on drug and medical device pricing, care pathway optimization, feasibility studies and cohort identification for clinical trials.
“We must ensure that we are ever more responsive and efficient to deliver quality care. Our ambitions in research and innovation are significant and reflect the ICO’s DNA across the care-research continuum. We must continue to modernize our approach to health data and strengthen our tools and systems,” concluded Professor Mario Campone, ICO’s Director General.
The partnership was launched after a thorough assessment by ARC experts of ICO’s current innovation capabilities. The collaboration also includes knowledge sharing sessions between ARC and ICO leaders, further aligning ICO’s objectives with ARC’s proven framework for healthcare transformation.
Caroline Haïat
Comments